JP2020503362A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020503362A5 JP2020503362A5 JP2019536919A JP2019536919A JP2020503362A5 JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5 JP 2019536919 A JP2019536919 A JP 2019536919A JP 2019536919 A JP2019536919 A JP 2019536919A JP 2020503362 A5 JP2020503362 A5 JP 2020503362A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- cdr
- fibrosis
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022162088A JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2024172672A JP2025000891A (ja) | 2017-01-06 | 2024-10-01 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443615P | 2017-01-06 | 2017-01-06 | |
| US62/443,615 | 2017-01-06 | ||
| US201762452866P | 2017-01-31 | 2017-01-31 | |
| US62/452,866 | 2017-01-31 | ||
| US201762514417P | 2017-06-02 | 2017-06-02 | |
| US62/514,417 | 2017-06-02 | ||
| US201762529616P | 2017-07-07 | 2017-07-07 | |
| US62/529,616 | 2017-07-07 | ||
| US201762549767P | 2017-08-24 | 2017-08-24 | |
| US62/549,767 | 2017-08-24 | ||
| US201762558311P | 2017-09-13 | 2017-09-13 | |
| US62/558,311 | 2017-09-13 | ||
| US201762585227P | 2017-11-13 | 2017-11-13 | |
| US62/585,227 | 2017-11-13 | ||
| US201762587964P | 2017-11-17 | 2017-11-17 | |
| US62/587,964 | 2017-11-17 | ||
| US201762588626P | 2017-11-20 | 2017-11-20 | |
| US62/588,626 | 2017-11-20 | ||
| PCT/US2018/012601 WO2018129329A1 (en) | 2017-01-06 | 2018-01-05 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162088A Division JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020503362A JP2020503362A (ja) | 2020-01-30 |
| JP2020503362A5 true JP2020503362A5 (enExample) | 2021-02-12 |
| JP7157744B2 JP7157744B2 (ja) | 2022-10-20 |
Family
ID=61198888
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536919A Active JP7157744B2 (ja) | 2017-01-06 | 2018-01-05 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2022162088A Pending JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2024172672A Pending JP2025000891A (ja) | 2017-01-06 | 2024-10-01 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022162088A Pending JP2022188226A (ja) | 2017-01-06 | 2022-10-07 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
| JP2024172672A Pending JP2025000891A (ja) | 2017-01-06 | 2024-10-01 | アイソフォーム特異的な、コンテクスト寛容ＴＧＦβ１阻害剤およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180207267A1 (enExample) |
| EP (1) | EP3551658A1 (enExample) |
| JP (3) | JP7157744B2 (enExample) |
| KR (2) | KR20190098255A (enExample) |
| CN (2) | CN110382530A (enExample) |
| AU (2) | AU2018205231A1 (enExample) |
| BR (1) | BR112019013908A2 (enExample) |
| CA (1) | CA3049005A1 (enExample) |
| CL (1) | CL2019001874A1 (enExample) |
| CO (1) | CO2019007298A2 (enExample) |
| CR (1) | CR20190350A (enExample) |
| DO (1) | DOP2019000180A (enExample) |
| IL (2) | IL267790A (enExample) |
| MX (1) | MX2019008197A (enExample) |
| PE (1) | PE20191661A1 (enExample) |
| PH (1) | PH12019501575A1 (enExample) |
| WO (1) | WO2018129329A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250011248A (ko) | 2016-03-11 | 2025-01-21 | 스칼러 락, 인크. | TGFβ1-결합 이뮤노글로불린 및 그의 용도 |
| BR112019013908A2 (pt) * | 2017-01-06 | 2020-02-04 | Scholar Rock, Inc. | inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos |
| MA49690A (fr) * | 2017-07-28 | 2021-05-19 | Scholar Rock Inc | Inhibiteurs spécifiques du complexe ltbp de tgf-bêta 1 et leurs utilisations |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| LT3677278T (lt) | 2018-07-11 | 2022-01-10 | Scholar Rock, Inc. | Izoformoms selektyvūs tgfbeta1 inhibitoriai ir jų panaudojimas |
| TW202019957A (zh) | 2018-07-11 | 2020-06-01 | 美商供石公司 | TGFβ1抑制劑及其用途 |
| AU2019302679A1 (en) | 2018-07-11 | 2021-02-11 | Scholar Rock, Inc. | High-affinity, isoform-selective TGFbeta1 inhibitors and use thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
| TW202043267A (zh) | 2019-01-30 | 2020-12-01 | 美商供石公司 | TGFβ之LTBP複合物專一性抑制劑及其用途 |
| TW202102207A (zh) * | 2019-03-27 | 2021-01-16 | 新加坡商新加坡保健服務集團有限公司 | 對於癌病具有治療意義的生物標記 |
| WO2020206055A1 (en) * | 2019-04-02 | 2020-10-08 | Yale University | Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| CN120025435A (zh) | 2019-08-28 | 2025-05-23 | 中外制药株式会社 | 跨物种抗潜伏TGF-β1抗体和使用方法 |
| EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| AU2021205433A1 (en) | 2020-01-11 | 2022-08-18 | Scholar Rock, Inc. | Tgfß inhibitors and use thereof |
| US20230050148A1 (en) * | 2020-01-11 | 2023-02-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| DK4045533T5 (da) | 2020-03-26 | 2024-07-29 | Univ Vanderbilt | Humane monoklonale antistoffer mod svær akut respiratorisk syndrom-coronavirus 2 (sars-cov-2) |
| US20230122364A1 (en) * | 2020-03-27 | 2023-04-20 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) |
| EP4142739A2 (en) | 2020-04-27 | 2023-03-08 | Twist Bioscience Corporation | Variant nucleic acid libraries for coronavirus |
| KR102913125B1 (ko) | 2020-06-03 | 2026-01-20 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| JP2023553861A (ja) * | 2020-12-02 | 2023-12-26 | 上海復宏漢霖生物技術股▲フン▼有限公司 | 抗ＧＡＲＰ／ＴＧＦβ抗体及び使用方法 |
| CN114957476A (zh) * | 2021-02-23 | 2022-08-30 | 复旦大学 | 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| CA3218917A1 (en) | 2021-05-11 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| WO2022241023A1 (en) | 2021-05-13 | 2022-11-17 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
| US20230125173A1 (en) * | 2021-08-11 | 2023-04-27 | HCW Biologics, Inc. | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| EP4667056A1 (en) | 2021-12-22 | 2025-12-24 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| LT4245756T (lt) | 2022-03-17 | 2024-11-25 | Gilead Sciences, Inc. | Ikaros cinko pirštų šeimos skaidymo medžiagos ir jų panaudojimas |
| CN119255993A (zh) | 2022-03-22 | 2025-01-03 | 奥托泰利克生物公司 | 噻唑衍生物化合物及其用途 |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| JP2026507882A (ja) | 2023-03-07 | 2026-03-06 | スカラー ロック インコーポレイテッド | 患者の抵抗性又は不応答性癌を治療するためのＴＧＦ－β阻害剤及びその使用 |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN117721079B (zh) * | 2024-01-26 | 2025-03-11 | 广东壹加再生医学研究院有限公司 | 一种促进nk细胞抗肿瘤活性的培养基及培养方法 |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| EP1541682A3 (en) | 1988-09-02 | 2005-07-06 | Dyax Corp. | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| DE69129154T2 (de) | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| ATE414768T1 (de) | 1991-04-10 | 2008-12-15 | Scripps Research Inst | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| US6015884A (en) | 1996-03-28 | 2000-01-18 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| CN101525384A (zh) | 2000-06-29 | 2009-09-09 | 艾博特公司 | 双特异性抗体及其制备方法和用途 |
| GB0230202D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Ligand |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| EP3520815B1 (en) | 2005-02-08 | 2021-11-17 | Genzyme Corporation | Antibodies to tgfbeta |
| EP2125894B1 (en) * | 2007-03-22 | 2018-12-19 | Biogen MA Inc. | Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| AR072000A1 (es) | 2008-06-03 | 2010-07-28 | Abbott Lab | Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| WO2011102483A1 (ja) * | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | ヒトTGF-βのLAPに結合する抗体 |
| UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| TW201527322A (zh) * | 2011-02-08 | 2015-07-16 | Abbvie Inc | 骨關節炎及疼痛之治療 |
| EP3954704A1 (en) * | 2011-06-03 | 2022-02-16 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| RU2014114015A (ru) * | 2011-11-08 | 2015-12-20 | Пфайзер Инк. | Способы лечения воспалительных расстройств с использованием антител против m-csf |
| RS56796B1 (sr) | 2011-11-14 | 2018-04-30 | Regeneron Pharma | Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a |
| WO2013134365A1 (en) * | 2012-03-08 | 2013-09-12 | Ludwig Institute For Cancer Research Ltd | TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF |
| SMT202100008T1 (it) * | 2013-05-06 | 2021-03-15 | Scholar Rock Inc | Composizioni e metodi per la modulazione di fattore di crescita |
| US20170073406A1 (en) * | 2014-05-06 | 2017-03-16 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| CA2973978A1 (en) * | 2015-01-14 | 2016-07-21 | The Brigham And Women's Hospital, Inc. | Treatment of cancer with anti-lap monoclonal antibodies |
| KR20250011248A (ko) | 2016-03-11 | 2025-01-21 | 스칼러 락, 인크. | TGFβ1-결합 이뮤노글로불린 및 그의 용도 |
| BR112019013908A2 (pt) * | 2017-01-06 | 2020-02-04 | Scholar Rock, Inc. | inibidores de tgfss1 isoforma-específicos, contexto-permissivos, e seus usos |
-
2018
- 2018-01-05 BR BR112019013908-7A patent/BR112019013908A2/pt unknown
- 2018-01-05 CN CN201880015969.2A patent/CN110382530A/zh active Pending
- 2018-01-05 WO PCT/US2018/012601 patent/WO2018129329A1/en not_active Ceased
- 2018-01-05 CN CN202310792211.2A patent/CN117398457A/zh active Pending
- 2018-01-05 KR KR1020197022663A patent/KR20190098255A/ko not_active Ceased
- 2018-01-05 JP JP2019536919A patent/JP7157744B2/ja active Active
- 2018-01-05 KR KR1020247030136A patent/KR20240137126A/ko not_active Ceased
- 2018-01-05 CA CA3049005A patent/CA3049005A1/en active Pending
- 2018-01-05 PE PE2019001372A patent/PE20191661A1/es unknown
- 2018-01-05 CR CR20190350A patent/CR20190350A/es unknown
- 2018-01-05 AU AU2018205231A patent/AU2018205231A1/en not_active Abandoned
- 2018-01-05 US US15/863,564 patent/US20180207267A1/en not_active Abandoned
- 2018-01-05 MX MX2019008197A patent/MX2019008197A/es unknown
- 2018-01-05 EP EP18705030.7A patent/EP3551658A1/en active Pending
-
2019
- 2019-03-22 US US16/361,486 patent/US20190209682A1/en not_active Abandoned
- 2019-07-02 IL IL267790A patent/IL267790A/en unknown
- 2019-07-03 PH PH12019501575A patent/PH12019501575A1/en unknown
- 2019-07-05 CL CL2019001874A patent/CL2019001874A1/es unknown
- 2019-07-05 DO DO2019000180A patent/DOP2019000180A/es unknown
- 2019-07-08 CO CONC2019/0007298A patent/CO2019007298A2/es unknown
-
2022
- 2022-10-07 JP JP2022162088A patent/JP2022188226A/ja active Pending
-
2023
- 2023-07-11 IL IL304416A patent/IL304416A/en unknown
- 2023-08-01 US US18/363,435 patent/US20240016928A1/en active Pending
-
2024
- 2024-10-01 JP JP2024172672A patent/JP2025000891A/ja active Pending
-
2025
- 2025-05-16 AU AU2025203555A patent/AU2025203555A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020503362A5 (enExample) | ||
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| JP5164829B2 (ja) | 新規な抗ｐｌｇｆ抗体 | |
| JP2011504501A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| CN106103479B (zh) | 识别其它ccr3-结合趋化因子的抗嗜酸粒细胞趋化因子-2抗体 | |
| CN112930356B (zh) | 与瓜氨酸化的组蛋白2a和/或4结合的抗体 | |
| JP2019505527A5 (enExample) | ||
| JP2016519650A5 (enExample) | ||
| JP2008518936A5 (enExample) | ||
| JP2010527356A5 (enExample) | ||
| JP2017537084A5 (enExample) | ||
| JP2018093875A5 (enExample) | ||
| JP2011518886A5 (enExample) | ||
| JP2017113019A5 (enExample) | ||
| CN103974976A (zh) | 用于治疗炎性病症的il17c拮抗剂 | |
| JP2017535285A5 (enExample) | ||
| JP2011518857A5 (enExample) | ||
| JP6383665B2 (ja) | ＩＬ‐１β中和ヒトモノクローナル抗体 | |
| JP2015518857A5 (enExample) | ||
| JPWO2020059847A5 (enExample) | ||
| JP2016006052A5 (enExample) | ||
| JP2015515490A5 (enExample) | ||
| JP2022542805A (ja) | メタロチオネイン抗体およびそれらの使用 | |
| WO2023108028A2 (en) | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof |